Mini-Focus: Stent Technology |
Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer
Robert A. Byrne, MB*,*,
Raisuke Iijima, MD*,
Julinda Mehilli, MD*,
Susanne Pinieck, RN*,
Olga Bruskina, MD*,
Albert Schömig, MD*, ,
Adnan Kastrati, MD*
* Deutsches Herzzentrum, Technische Universität, Munich, Germany
1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany
* Reprint requests and correspondence: Dr. Robert A. Byrne, ISAR Centre, Deutsches Herzzentrum München, Lazarettstrasse 36, 80636 Munich, Germany (Email: byrne{at}dhm.mhn.de).
Objectives: We sought to assess changes in antirestenotic efficacy of drug-eluting stents (DES) by restudying subjects at 2 time points after coronary stenting (6 to 8 months and 2 years) and to compare differences in time courses of late luminal loss (LLL) between 3 different DES platforms in use at our institution.
Background: DES therapy is associated with low levels of LLL at 6 to 8 months. The temporal course of neointimal formation after this time point remains unclear.
Methods: This prospective, observational, systematic angiographic follow-up study was conducted at 2 centers in Munich, Germany. Patients underwent stenting with permanent-polymer rapamycin-eluting stents (RES), polymer-free RES, or permanent-polymer paclitaxel-eluting stents (PES). The primary end point was delayed LLL (the difference in in-stent LLL between 6 to 8 months and 2 years).
Results: Of 2,588 patients undergoing stenting, 2,030 patients (78.4%) had 6- to 8-month angiographic follow-up and were enrolled in the study. Target lesion revascularization was performed in 259 patients; these patients were not considered for further angiographic analysis. Of 1,771 remaining patients, 1,331 had available 2-year reangiographic data (75.2%). Overall mean (SD) delayed LLL was 0.12 ± 0.49 mm (0.17 ± 0.50 mm, 0.01 ± 0.42 mm, and 0.13 ± 0.50 mm in permanent-polymer RES, polymer-free RES, and permanent-polymer PES groups, respectively [p < 0.001]). In multivariate analysis, only stent type (in favor of polymer-free RES) predicted delayed LLL.
Conclusions: Ongoing erosion of luminal caliber beyond 6 to 8 months after the index procedure is observed following DES implantation. Absence of permanent polymer from the DES platform seems to militate against this effect.
Key Words: coronary restenosis stents/adverse effects follow-up studies cell proliferation/drug effects immunosuppressive agents/therapeutic uses polymers 2-year reangiography
|
Abbreviations and Acronyms
| | BMS = bare-metal stent(s) | | DES = drug-eluting stent(s) | | LLL = late luminal loss | | PES = paclitaxel-eluting stent(s) | | RES = rapamycin-eluting stent(s) | | TLR = target lesion revascularization |
|
Related Article
-
Temporal Course of Neointimal Formation After Drug-Eluting Stent Placement: Is Our Understanding of Restenosis Changing?
- Aloke V. Finn, Gaku Nakazawa, Frank D. Kolodgie, and Renu Virmani
J. Am. Coll. Cardiol. Intv. 2009 2: 300-302.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
C. A. Collet, J. R. Costa, A. Abizaid, D. Chamie, R. Staico, R. Costa, D. Siquera, J. Obregon, F. Feres, A. Sousa, et al.
Assessing the Temporal Course of Neointimal Hyperplasia Formation After Different Generations of Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1067 - 1074.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Raber and P. W. Serruys
Late Vascular Response Following Drug-Eluting Stent Implantation
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1075 - 1078.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Raber, P. Juni, E. Nuesch, B. Kalesan, P. Wenaweser, A. Moschovitis, A. A. Khattab, M. Bahlo, M. Togni, S. Cook, et al.
Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
J. Am. Coll. Cardiol.,
May 24, 2011;
57(21):
2143 - 2151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. W. Stone, S. G. Ellis, A. Colombo, E. Grube, J. J. Popma, T. Uchida, J. S. Bleuit, K. D. Dawkins, and M. E. Russell
Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents: Final 5-Year Analysis From the TAXUS Clinical Trial Program
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
530 - 542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Desch, D. Schloma, S. Mobius-Winkler, S. Erbs, S. Gielen, A. Linke, J. Yu, B. Lauer, K. Kleinertz, W. Danschel, et al.
Randomized Comparison of a Polymer-Free Sirolimus-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent in Patients With Diabetes Mellitus: The LIPSIA Yukon Trial
J. Am. Coll. Cardiol. Intv.,
April 1, 2011;
4(4):
452 - 459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kastrati and R. Byrne
New Roads, New Ruts: Lessons From Drug-Eluting Stent Restenosis
J. Am. Coll. Cardiol. Intv.,
February 1, 2011;
4(2):
165 - 167.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kuriyama, Y. Kobayashi, T. Nakama, D. Mine, K. Nishihira, M. Shimomura, K. Nomura, K. Ashikaga, A. Matsuyama, and Y. Shibata
Late Restenosis Following Sirolimus-Eluting Stent Implantation
J. Am. Coll. Cardiol. Intv.,
January 1, 2011;
4(1):
123 - 128.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Niccoli, R. A. Montone, G. Ferrante, and F. Crea
The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation
J. Am. Coll. Cardiol.,
November 23, 2010;
56(22):
1783 - 1793.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Garg and P. W. Serruys
Coronary Stents: Looking Forward
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S43 - S78.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Mehilli, R. A. Byrne, K. Tiroch, S. Pinieck, S. Schulz, S. Kufner, S. Massberg, K.-L. Laugwitz, A. Schomig, A. Kastrati, et al.
Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study
J. Am. Coll. Cardiol.,
June 15, 2010;
55(24):
2710 - 2716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Byrne, A. Kastrati, K. Tiroch, S. Schulz, J. Pache, S. Pinieck, S. Massberg, M. Seyfarth, K.-L. Laugwitz, K. A. Birkmeier, et al.
2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents
J. Am. Coll. Cardiol.,
June 8, 2010;
55(23):
2536 - 2543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. B. Leon, D. E. Kandzari, E. L. Eisenstein, K. J. Anstrom, L. Mauri, D. E. Cutlip, E. Nikolsky, C. O'Shaughnessy, P. A. Overlie, A. J. Kirtane, et al.
Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions: 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1208 - 1218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Finn, G. Nakazawa, F. D. Kolodgie, and R. Virmani
Temporal Course of Neointimal Formation After Drug-Eluting Stent Placement: Is Our Understanding of Restenosis Changing?
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
300 - 302.
[Full Text]
[PDF]
|
 |
|
|